Clinical TrialsBlinded interim analysis of the TTI-101 trial revealed a positive trend on forced vital capacity, and an independent monitoring committee recommended the trial should continue.
Market PotentialTTI-101 has the potential to emerge as a cornerstone therapy in the multi-billion idiopathic pulmonary fibrosis market, possibly achieving significant worldwide sales.
Therapeutic AdvancementsTvardi Therapeutics' lead compound, TTI-101, demonstrates superior performance in reducing IPF-induced genes compared to standard of care treatments.